SCHIZOPHRENIA · White paper
Schizophrenia Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About schizophrenia — and why its trials are hard
Schizophrenia is a chronic, severe psychiatric disorder marked by positive symptoms (hallucinations, delusions, disorganized thinking), negative symptoms (affective flattening, avolition, anhedonia) and cognitive deficits, typically emerging in late adolescence or early adulthood. It affects roughly 24 million people worldwide (about 0.32% of the population) and carries heritability estimated near 80%, alongside dopamine, glutamate and serotonin dysregulation. For decades pharmacotherapy relied on typical and atypical antipsychotics that block dopamine D2 receptors; clozapine remains uniquely effective in treatment-resistant disease and in reducing suicidality. In 2024 the FDA approved xanomeline-trospium (Cobenfy), the first agent acting through a non-D2, muscarinic (M1/M4) mechanism, a landmark shift in a field long dominated by dopamine antagonism. Clinical trials center on PANSS/BPRS symptom change but are challenged by high and variable placebo response, symptom heterogeneity, subjective self-report, cognitive-measurement complexity and long follow-up for relapse endpoints, contributing to a high historical failure rate for novel mechanisms.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Clozapine (Clozaril) | 1989 | Treatment-resistant schizophrenia; reduction of recurrent suicidal behavior | Pivotal clozapine vs chlorpromazine trial; InterSePT (vs olanzapine) | BPRS/CGI-S response; time to significant suicide attempt | Response rate 30% (clozapine) vs 4% (chlorpromazine); BPRS change -16 vs -5 (p<0.001) |
| Risperidone (Risperdal / Risperdal Consta) | 1993 | Schizophrenia (oral and long-acting injectable) | 12-week placebo-controlled trial (Risperdal Consta) | PANSS total score change | Significant PANSS improvement vs placebo at 25/50/75 mg doses |
| Olanzapine (Zyprexa) | 1996 | Acute and maintenance schizophrenia (adults and adolescents) | 6-week placebo-controlled trials; longer-term relapse-prevention trial | PANSS/BPRS total; time to relapse | 10 mg/day superior to placebo on PANSS/BPRS; superior relapse prevention (trial stopped early for excess placebo relapses) |
| Quetiapine (Seroquel / Seroquel XR) | 1997 | Acute and maintenance schizophrenia | 6-week fixed-dose placebo-controlled trial; maintenance relapse trial | PANSS total change; time to relapse | PANSS change -30.9 (XR 600 mg) vs -18.8 placebo; significantly longer time to relapse (relapse = >=30% PANSS increase) |
| Aripiprazole (Abilify) | 2002 | Schizophrenia (D2/5-HT1A partial agonist); LAI formulations available | Multiple 4-6 week placebo-controlled trials; 26-week relapse trial | PANSS total change; time to relapse | PANSS change ~-15 (10-15 mg) vs ~-2 to -5 placebo; 15 mg/day significantly delayed relapse |
| Xanomeline-trospium (Cobenfy) | 2024 | Schizophrenia in adults; first-in-class M1/M4 muscarinic agonist (non-D2 mechanism) | EMERGENT-2 / EMERGENT-3 (5-week Phase 3) | Change in PANSS total score at Week 5 | EMERGENT-2: PANSS -21.2 vs -11.6 placebo, treatment difference approximately -9.6 (p<0.0001) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in schizophrenia development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Pomaglumetad methionil (LY2140023) — Eli Lilly Phase 2/3 program | Failed to separate from placebo on PANSS; development discontinued | mGluR2/3 agonist mechanism did not confirm efficacy; high placebo response and patient heterogeneity |
| Bitopertin — Roche Phase 3 (negative-symptom program) | Did not meet primary endpoint for negative symptoms as adjunctive therapy | Glycine reuptake (GlyT1) inhibition failed to translate to clinical benefit; difficulty measuring negative-symptom change |
| Roluperidone (MIN-101) — Phase 3 negative-symptom trial | FDA declined approval; efficacy/data package deemed insufficient | Modest effect size on negative symptoms and reliance on a single pivotal study |
Choosing the right endpoint
Primary endpoints that matter in schizophrenia trials
- PANSS total score change — Primary efficacy standard (Positive and Negative Syndrome Scale); high placebo response complicates separation
- BPRS — Brief Psychiatric Rating Scale; used in older trials such as the pivotal clozapine studies
- CGI-S / CGI-I — Clinician Global Impression of severity/improvement; supportive global measure
- Time to relapse — Key maintenance endpoint; definitions vary (hospitalization, PANSS increase, medication change), requiring long follow-up
- Cognitive function (MCCB) — MATRICS Consensus Cognitive Battery standardizes cognitive-domain assessment, a difficult secondary endpoint
How iNGENū runs schizophrenia trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Schizophrenia clinical trials — FAQs
What is the primary efficacy endpoint in schizophrenia trials?
Why is Cobenfy (xanomeline-trospium) considered a landmark approval?
Why do so many schizophrenia trials fail?
Related
Explore more
Ready to discuss your schizophrenia trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal